Patient profile 56-year-old male sustained frostbite injury to his left hand after a 4-hour exposure to the cold. His attempt to re-warm the digits under warm water was unsuccessful. Medical history Prior medical history includes • depression Current medication: • diphenhydramine • hydrocodone/acetaminophen • ziprasidone • multi-vitamin Treatment Day 1 Necrotic tissue was debrided with three digit amputations. Day 5 The patient was seen in the clinic. Silver sulfadiazine was prescribed. Day 14 Tissue was further surgically debrided. OASIS ULTRA Tri-Layer Matrix was applied and secured with sutures. Day 19-84 OASIS Wound Matrix was applied and secured with adhesive skin closures. In the following months, the wounds continued to decrease in size and progress towards closure. Day 208 With the use of OASIS ULTRA and OASIS Wound Matrix, the frostbite amputation sites attained full closure and allowed the patient to preserve digit length. Case study: Finger frostbite Contributed by Kenneth Moquin, MD, MS Individual results will vary. Day 1: prior to debridement Day 5: 4 days following amputation Day 14: post debridement, OASIS ULTRA applied Day 19: OASIS ULTRA applied
Transcript
Patient profile
56-year-old male sustained frostbite injury to his left hand after a 4-hour exposure to the cold. His attempt to re-warm the digits under warm water was unsuccessful.
Medical historyPrior medical history includes • depression
Current medication:• diphenhydramine • hydrocodone/acetaminophen • ziprasidone • multi-vitamin
Treatment
Day 1 Necrotic tissue was debrided with three digit amputations.
Day 5 The patient was seen in the clinic. Silver sulfadiazine was prescribed.
Day 14 Tissue was further surgically debrided. OASIS ULTRA Tri-Layer Matrix was applied and secured with sutures.
Day 19-84 OASIS Wound Matrix was applied and secured with adhesive skin closures. In the following months, the wounds continued to decrease in size and progress towards closure.
Day 208 With the use of OASIS ULTRA and OASIS Wound Matrix, the frostbite amputation sites attained full closure and allowed the patient to preserve digit length.
Case study: Finger frostbiteContributed by Kenneth Moquin, MD, MS
Individual results will vary.
Treatment: Day 1 • Necrotic tissue was debrided with three digit amputations.
4
Necrotic tissue debrided Frostbite injury prior to debridement
Case: Finger frostbite Contributed by Kenneth Moquin, MD, MS
4
Day 1: prior to debridement Day 5: 4 days following amputation Day 14: post debridement, OASIS ULTRA applied Day 19: OASIS ULTRA applied
Treatment: Day 5 • The patient was seen in the clinic. Silver sulfadiazine was prescribed.
5
4 days following digit amputation 4 days following digit amputation
Case: Finger frostbite Contributed by Kenneth Moquin, MD, MS
5 6
Post-debridement OASIS ULTRA applied
Treatment: Day 14 • Tissue was further surgically debrided. OASIS ULTRA Tri-Layer Matrix was
applied and secured with sutures.
OASIS ULTRA secured
Case: Finger frostbite Contributed by Kenneth Moquin, MD, MS
Note: Individual results will vary.
Treatment: Day 19 – 84 • Day 19: OASIS Wound Matrix was applied and secured with adhesive skin
closures. In the following months, the wounds continued to decrease in size and progress towards closure.
7
Case: Finger frostbite Contributed by Kenneth Moquin, MD, MS
Note: Individual results will vary. 7
Day 19: OASIS Matrix applied Day 33 Day 84
Manufactured by: Cook Biotech, Inc. 1425 Innovation Place West Lafayette, IN 47906
Distributed by: Advanced Wound Management Smith & Nephew, Inc. Fort Worth, TX 76109 USA
www.smith-nephew.com www.oasiswoundmatrix.comCustomer Care Center:1 800 441-8227 T 817 900-4000F 817 900-4100 Supporting healthcare professionals for over 150 years
Contraindications: This device is derived from a porcine source and should not be used in patients with known sensitivity to porcine material. This device is not indicated for use in third-degree burns.
Precaution: OASIS Matrix Products should not be applied until excessive exudate, bleeding, acute swelling, and infection are controlled.
Potential complications: The following complications are possible. If any of these conditions occur, the device should be removed: infection, chronic inflammation (initial application of wound dressings may be associated with transient, mild, localized inflammation), allergic reaction, excessive redness, pain, swelling, or blistering.
Storage: This device should be stored in a clean, dry location at room temperature.
For information regarding reimbursement, call the OASIS Navigator Hotline at 1-877-805-5005.
Individual results will vary.
Day 33 Day 84 Day 208
Treatment: Day 19 – 84 • Day 19: OASIS Wound Matrix was applied and secured with adhesive skin
closures. In the following months, the wounds continued to decrease in size and progress towards closure.
7
Case: Finger frostbite Contributed by Kenneth Moquin, MD, MS
Note: Individual results will vary. 7
Day 19: OASIS Matrix applied Day 33 Day 84
Treatment: Day 19 – 84 • Day 19: OASIS Wound Matrix was applied and secured with adhesive skin
closures. In the following months, the wounds continued to decrease in size and progress towards closure.
7
Case: Finger frostbite Contributed by Kenneth Moquin, MD, MS
Note: Individual results will vary. 7
Day 19: OASIS Matrix applied Day 33 Day 84
Results: Day 208 • With the use of OASIS ULTRA and OASIS Wound Matrix, the frostbite
amputation sites attained full closure and allowed the patient to preserve digit length.
8
Case: Finger frostbite Contributed by Kenneth Moquin, MD, MS
8 Note: Individual results will vary.
Results: With the use of OASIS® ULTRA and OASIS® Wound Matrix, the frostbite amputation sites attained full closure and the patient preserved digit length.
For detailed product information, please consult the product’s Instructions for Use (IFU) prior to use.
Individual results will vary.
Patient profileA 32-year-old female with a history of seizures presented with deep thermal burns sustained from falling into a hot water boiler during a seizure. Second-degree burns were sustained to face and neck, with measurements as follows:
• Face, neck, ears, eyelids, nose: 30cm x 30cm
Patient was taking gabapentin 300mg once daily and phenytoin 100mg (2 tablets) once daily for epilepsy.
Case history Mechanical debridement of necrotic tissue and eschar was performed with a combination of surgical blades and abrasive pad dermabrasion. Wounds were cleaned with chlorhexidine and lap pad.
Results
Within one month after debridement and a single application of OASIS ULTRA Tri-Layer Matrix, the burn wounds were closed and the patient reported being satisfied with the results.
TreatmentDay 1: Immediately following debridement, dermabrasion, and cleaning, OASIS ULTRA Tri-Layer Matrix was placed into position on the face, moistened, and cut to fit the contours of the injured area. Once dried, OASIS ULTRA Tri-Layer Matrix was then fixed into position with Dermabond™ Topical Skin Adhesive.
Month 1: Final closure of second-degree facial burns was noted less than one month after debride-ment and one-time application of OASIS ULTRA Tri-Layer Matrix.
OASIS ULTRA Tri-Layer Matrix is not indicated for use in third-degree burns.
Case study: Acute traumatic second-degree burn of faceContributed by Louis Riina MD
Burns at presentation Application of OASIS ULTRA Tri-Layer Matrix Final results
References: 1. Data on file. Cook Biotech, Inc. 2.Badylak SF. The extracellular matrix as a scaffold for tissue reconstruction. Semin Cell Dev Biol 2002;1315):377-383.
Manufactured by: Cook Biotech, Inc. 1425 Innovation Place West Lafayette, IN 47906
Distributed by: Advanced Wound Management Smith & Nephew, Inc. Fort Worth, TX 76109 USA
www.smith-nephew.com www.oasiswoundmatrix.comCustomer Care Center:1 800 441-8227 T 817 900-4000F 817 900-4100 Supporting healthcare professionals for over 150 years
For detailed product information, please consult the product’s Instructions for Use (IFU) prior to use.For information regarding reimbursement, call the OASIS Navigator Hotline at 1-877-805-5005.
OASIS® Matrix Products are composed of porcine small intestinal submucosa (SIS), a naturally derived, strong scaffold of extracellular matrix (ECM)1
• Porcine SIS provides pathways for cellular migration and vascular ingrowth2 Porcine SIS ECM
Contraindications: This device is derived from a porcine source and should not be used in patients with known sensitivity to porcine material. This device is not indicated for use in third-degree burns.
Precaution: OASIS Matrix Products should not be applied until excessive exudate, bleeding, acute swelling, and infection are controlled.
Potential complications: The following complications are possible. If any of these conditions occur, the device should be removed: infection, chronic inflammation (initial application of wound dressings may be associated with transient, mild, localized inflammation), allergic reaction, excessive redness, pain, swelling, or blistering.
Storage: This device should be stored in a clean, dry location at room temperature.
Results:
4 weeks after initiation of OASIS ULTRA Tri-Layer Matrix, the wound advanced toward closure with a total of 3 applications.
Following resolution of the open diabetic foot ulcer, the patient was immediately scheduled for a revision total hip arthroplasty.
Individual results will vary.
Initial presentation Treatment with OASIS ULTRA Tri-Layer Matrix
One month after initiation with OASIS Ultra Tri-Layer Matrix
Patient profileA 57-year-old male veteran with a chronic diabetic foot ulcer.
Case historyThe patient’s hip prosthesis was removed due to infection, but the orthopedic team would not proceed with surgical revision until the diabetic foot ulcer was closed.
Medical historyChronic renal disease, diabetes mellitus, dyslipidemia, hypertension, peripheral neuropathy, septic polyarthritis, tobacco use, multiple toe amputations, and hip prosthesis.
TreatmentInitial presentation: Patient presented with a chronic ulcer to the plantar aspect of the 1st metatarsal head measuring L 1.7cm x W 1.5cm x D 0.2cm.
Initial treatment: Included standard of care with proper offloading, debridement, and a dry sterile dressing.
Post initial treatment: After 4 weeks of standard care, OASIS® ULTRA Tri-layer Matrix applied to wound, ulcer measured L 1.1cm x W 0.6cm x D 0.1cm.The decision was made to move to an advanced modality treatment.
Treatment with OASIS: OASIS ULTRA Tri-Layer Matrix was applied to the wound. Two additional applications of OASIS ULTRA were applied at weekly intervals.
Case study:
Diabetic foot ulcerContributed by Gary M. Rothenberg, DPM, CDE, CWS, Miami, FL
Manufactured by: Cook Biotech, Inc. 1425 Innovation Place West Lafayette, IN 47906
Distributed by: Advanced Wound Management Smith & Nephew, Inc. Fort Worth, TX 76109 USA
www.smith-nephew.com www.oasiswoundmatrix.comCustomer Care Center:1 800 441-8227 T 817 900-4000F 817 900-4100 Supporting healthcare professionals for over 150 years
For detailed product information, please consult the product’s Instructions for Use (IFU) prior to use.For information regarding reimbursement, call the OASIS Navigator Hotline at 1-877-805-5005.
Contraindications: This device is derived from a porcine source and should not be used in patients with known sensitivity to porcine material. This device is not indicated for use in third-degree burns.
Precaution: OASIS Matrix Products should not be applied until excessive exudate, bleeding, acute swelling, and infection are controlled.
Potential complications: The following complications are possible. If any of these conditions occur, the device should be removed: infection, chronic inflammation (initial application of wound dressings may be associated with transient, mild, localized inflammation), allergic reaction, excessive redness, pain, swelling, or blistering.
Storage: This device should be stored in a clean, dry location at room temperature.
Results:
The patient’s wound was completely resolved, and she was extremely satisfied with the functional and aesthetic outcome.
Individual results will vary.
Day 1 Day 25 Day 29 Day 56
Patient profilePatient was a 44-year-old female with a more than 20-year history of extensive sun exposure and year-round tanning bed use. She was seeing a private practice dermatologist who had excised multiple lesions from her legs. Additional lesions began to develop rapidly to the point where she was referred to an academic university for further assistance in management. From August 2010 to January 2011, sites on her legs, chest, cheek, and hands were found to be positive for squamous cell carcinoma.
Case historyDuring a scheduled Mohs surgery for a cancer on another site, a lesion of the left dorsal hand was biopsied and found to be squamous cell carcinoma. Mohs micrographic surgery was performed and treated the tumor in one stage. She had previous wounds managed with OASIS® Wound Matrix.
TreatmentDay 1: The primary defect measured 2.0cm W x 1.8cm H and extended down to the level of the subcutis. The patient had been prescribed cephalexin 500 mg twice daily for 7 days. VaselineTM was applied over OASIS ULTRA Tri-Layer Matrix to fill in the wound, and a Vaseline gauze dressing was placed over the wound and covered with a CobanTM Wrap. After a week, the wound was cleaned with a diluted vinegar solution at least twice a day and Vaseline was reapplied. The wound dressings, including OASIS ULTRA, were changed every 5-7 days until the wound was resolved.
Day 25: Wound appeared to be improving, and the patient was very pleased with OASIS Ultra. She noticed a difference compared to previous procedures. A significant amount of caramelization was seen. Caramelization is a normal and expected gel-like material associated with product progression.
Day 29: The site where OASIS Ultra was applied continued to improve with minimal patient concerns or complaints.
Day 56: Patient came in for routine wound check (3 months since surgery) and the wound was completely resolved. Patient was extremely satisfied with the functional and aesthetic outcome.
Case Study: Post-Mohs Surgery on Dorsal HandContributed by Ally-Khan Somani M.D., PhDAssistant Professor, Director of Dermatologic Surgery & Cutaneous Oncology Division, Indiana University of Medicine
Patient was a 44-year-old female with more than a 20 year history of extensive sun exposure and year-round tanning bed use who presented with multiple sites of concern. She was seeing a private practice dermatologist who had excised multiple lesions from her legs. Additional lesions began to develop rapidly to the point where she was referred to an academic university for further assistance in management. From August of 2010 to January of 2011, sites on her legs, chest, cheek, and hands were found to be positive for squamous cell carcinoma.
Case History • DuringascheduledMohssurgery foracanceronanothersite,a lesionoftheleftdorsalhandwas biopsiedandfoundtobesquamous cellcarcinoma.Mohsmicrographic surgerywasperformedandtreated thetumorinonestage.Shehad previouswoundsmanagedwith OASIS®WoundMatrix.
Case Study: Post-Mohs Surgery on Dorsal HandContributed by Ally-Khan Somani M.D., PhDAssistant Professor, Director of Dermatologic Surgery & Cutaneous Oncology Division, Indiana University of Medicine
Patient was a 44-year-old female with more than a 20 year history of extensive sun exposure and year-round tanning bed use who presented with multiple sites of concern. She was seeing a private practice dermatologist who had excised multiple lesions from her legs. Additional lesions began to develop rapidly to the point where she was referred to an academic university for further assistance in management. From August of 2010 to January of 2011, sites on her legs, chest, cheek, and hands were found to be positive for squamous cell carcinoma.
Case History • DuringascheduledMohssurgery foracanceronanothersite,a lesionoftheleftdorsalhandwas biopsiedandfoundtobesquamous cellcarcinoma.Mohsmicrographic surgerywasperformedandtreated thetumorinonestage.Shehad previouswoundsmanagedwith OASIS®WoundMatrix.
Case Study: Post-Mohs Surgery on Dorsal HandContributed by Ally-Khan Somani M.D., PhDAssistant Professor, Director of Dermatologic Surgery & Cutaneous Oncology Division, Indiana University of Medicine
Patient was a 44-year-old female with more than a 20 year history of extensive sun exposure and year-round tanning bed use who presented with multiple sites of concern. She was seeing a private practice dermatologist who had excised multiple lesions from her legs. Additional lesions began to develop rapidly to the point where she was referred to an academic university for further assistance in management. From August of 2010 to January of 2011, sites on her legs, chest, cheek, and hands were found to be positive for squamous cell carcinoma.
Case History • DuringascheduledMohssurgery foracanceronanothersite,a lesionoftheleftdorsalhandwas biopsiedandfoundtobesquamous cellcarcinoma.Mohsmicrographic surgerywasperformedandtreated thetumorinonestage.Shehad previouswoundsmanagedwith OASIS®WoundMatrix.
Case Study: Post-Mohs Surgery on Dorsal HandContributed by Ally-Khan Somani M.D., PhDAssistant Professor, Director of Dermatologic Surgery & Cutaneous Oncology Division, Indiana University of Medicine
Patient was a 44-year-old female with more than a 20 year history of extensive sun exposure and year-round tanning bed use who presented with multiple sites of concern. She was seeing a private practice dermatologist who had excised multiple lesions from her legs. Additional lesions began to develop rapidly to the point where she was referred to an academic university for further assistance in management. From August of 2010 to January of 2011, sites on her legs, chest, cheek, and hands were found to be positive for squamous cell carcinoma.
Case History • DuringascheduledMohssurgery foracanceronanothersite,a lesionoftheleftdorsalhandwas biopsiedandfoundtobesquamous cellcarcinoma.Mohsmicrographic surgerywasperformedandtreated thetumorinonestage.Shehad previouswoundsmanagedwith OASIS®WoundMatrix.
Case study: Post-Mohs surgery on dorsal hand Contributed by Ally-Khan Somani, M.D., PhDThe information contained herein was prepared exclusively by Dr. Ally-Khan Somani. The views and opinions expressed in this presentation are those of the presenter and do not reflect the position, opinion, or guidelines for clinical care of any other person, institution, scientific association, or product manufacturer. Smith & Nephew does not provide medical advice. It is the treating health care provider’s responsibility to determine the best course of treatment for their patient based upon his professional medical judgment. The presenter is a paid consultant of Smith & Nephew. The presenter receives royalty payments from the sale of the OASIS Matrix Products.
Manufactured by: Cook Biotech, Inc. 1425 Innovation Place West Lafayette, IN 47906
Distributed by: Advanced Wound Management Smith & Nephew, Inc.
www.smith-nephew.com www.oasiswoundmatrix.comCustomer Care Center:1 800 441-8227 T 817 900-4000F 817 900-4100 Supporting healthcare professionals for over 150 years
For information regarding reimbursement, call the OASIS Navigator Hotline at 1-877-805-5005.
Contraindications: This device is derived from a porcine source and should not be used in patients with known sensitivity to porcine material. This device is not indicated for use in third-degree burns.
Precaution: OASIS Matrix Products should not be applied until excessive exudate, bleeding, acute swelling, and infection are controlled.
Potential complications: The following complications are possible. If any of these conditions occur, the device should be removed: infection, chronic inflammation (initial application of wound dressings may be associated with transient, mild, localized inflammation), allergic reaction, excessive redness, pain, swelling, or blistering.
Storage: This device should be stored in a clean, dry location at room temperature.
For detailed product information, please consult the product’s Instructions for Use (IFU) prior to use.
